🇺🇸 FDA
Patent

US 7345060

Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

granted A61KA61K31/439A61K31/445

Quick answer

US patent 7345060 (Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity) held by Theravance, Inc. expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/439, A61K31/445, A61K31/4545, A61P